Tempus AI announced the publication of its study, 'Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer,' in JAMA Network Open. The study highlights the benefits of concurrent RNA- and DNA-based next-generation sequencing (NGS) in advanced cancer care.
The retrospective study involved over 5,500 patients with advanced non-small cell lung cancer (NSCLC). It found that concurrent RNA and DNA sequencing led to a 15.3% increase in identifying patients with actionable structural variants compared to DNA sequencing alone, and more than doubled the detection of emerging, rare structural variants.
These findings suggest that the concurrent use of RNA and DNA testing should be more widely implemented in clinical settings to maximize the detection of structural variants. This combined approach enhances clinicians' ability to provide more personalized treatment options for patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.